Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good afternoon and welcome to the Camurus Q2 2026 financial report. During the question and answer session, participants on the call will be able to ask questions by dialing pound key five on the telephone keypad. Now I will hand the conference over to CEO Fredrik Tiberg. Please go ahead.
Thank you so much and good day, everyone, and welcome to Camurus' second quarter 2026 results call. Thank you for joining us. Before we begin, please take note of our forward-looking statements which apply throughout today's presentation. Turning to the agenda, we will start with highlights, moving over to financial and commercial performance reviews. Before finishing with a short R&D pipeline update. Key takeaways. And then, of course, a Q&A session; with me on the call today are Anders Vadsholt, our Chief Financial Officer, and Richard Jameson, our Chief Commercial Officer. So, let me start with some highlights. I'm very pleased to report a solid second quarter, marking a clear return to growth after a softer start of the year for Camurus. Total revenues were 702 million SEK, up 4% year-on-year and 32% sequentially, with an operating result of 293 million SEK, corresponding to a 42% margin and finishing with 4.1 billion SEK in cash. Commercially, product sales reached a record of 528 million SEK. It is the first time we have been above half a billion in a quarter. Buvidal grew 12% year on year and 24% over the quarter. Brixadi royalties in the US increased 42%, and the Oczyesa launch continued in our first-wave European markets. In the pipeline, we received a complete response letter for the acromegaly and the GEP-NET indication in the US in June, which I will cover and come back to later in the presentation. Elsewhere, SORENTO continued to progress towards its primary analysis. We advanced CAM2056 Phase IIb preparations. Eli Lilly expanded our collaboration by exercising its option to include Amylin receptor agonists. And with that, Anders will now take over and go through the financials.
Thank you, Fredrik. The financial figures clearly demonstrate strength, which is encouraging. Looking beyond the headline numbers presented by Fredrik, if you strip out the one-off milestones, our underlying product and royalty revenue has grown from around 445 million in Q2 2024 to 559 million last year, and now reaching 655 million this quarter. This reflects a compounded annual growth rate of around 21%, with Buvidal showing stable growth and Brixadi royalties almost tripling as Braeburn sales in the US over a two-year period. Marketing and distribution expenses rose from 108 to 175 million SEK, reflecting our expanding commercial operations and sales growth. At the same time, R&D costs declined from 172 million to 125 million following the completion of multiple trials, signaling a favorable change in our cost structure as we shift towards commercial execution; administrative costs have increased to support the high level of activity. Regarding profitability. The operational result reached 293 million SEK this quarter, up from 292 million SEK last year. Although year-on-year figures appear similar, they conceal an improvement. Last year's figure included a significant milestone of 150 million, whereas this year's milestone was 46 million. The core margin is clearly improving. Earnings per share were 4.05 Swedish kronor. Our cash position at the end of the quarter was 4.1 billion, up from around 3.9 billion at the start, reflecting a rise of approximately 190 million. The primary factor for the net cash flow came from operating activities, which contributed 338 million SEK before working capital adjustments. This was partially offset by a 104 million outflow in working capital, mainly due to higher trade receivables and increased inventory to support the growing demand for Buvidal, along with 41 million invested primarily to set up a second manufacturer. Importantly, we remain debt-free, which gives us real flexibility as we look ahead regarding capital allocation for the rest of 2026. Our main priorities are clear: to finance the organic growth of the business, including commercial expansion and pipeline development, while maintaining a strong and flexible balance sheet to support partnerships and business opportunities as they emerge. On the cost side, we are allocating an additional 200 million to expand our commercial activities, particularly for the US team to support the upcoming Oczyesa launch and to prepare for CAM2029 in GEP-NET. Furthermore, we intend to invest an additional 150 million in R&D for the planned new clinical trials. These investments will be funded from our own cash flow. Despite the CRL for acromegaly, we reaffirm our full-year guidance. And with that, I'll hand over to Richard for the commercial update. Thanks, Anders.
So I will start with Buvidal. In Q2, Buvidal delivered a record quarter with net sales of 524 million SEK. This is up 12% year-on-year and 24% sequentially, and in-market sales were up 19% versus the same period last year and 6% quarter-on-quarter, which reflect strong underlying demand. Growth was broad-based across geographies, including the Nordics, Germany, Spain, and France, and the UK saw improving sales as new NHS funding started to become available. Australia was steady, with prescribing capacity in parts of the market being a limiting factor that we are addressing with clinics and providers. Buvidal remains the clear leader there, with over 80% of the LAIB segment and an overall market share of patients above 30% in Australia. At the end of the quarter, it was announced that the other long-acting buprenorphine product is being withdrawn from the market by the end of 2026. The product has a minority share of the long-acting injectable buprenorphine segment, and our priority in this regard will be to ensure continuity of care for patients working with clinics, as we've done in similar transitions in Sweden, Finland, and Germany. We ended the quarter with an estimated 77,000 patients in treatment, up a net 4,000, and we're on track towards the 100,000 patient ambition by the end of 2027. Now, turning to the US, Brixadi continued to grow well in the US. Royalty revenue rose 42% year-on-year to 127 million SEK. That was up 20% sequentially. That makes it a record royalty quarter and a clear re-acceleration after the seasonal softness we saw in the first quarter. Demand was solid across office-based care treatment centers and correctional facilities. Importantly, this growth is happening in an expanding market. The US long-acting injectable segment is now estimated to be around $1.2 billion on an annualized basis and growing more than 30% year-on-year. Yet it still represents only about 10% of the roughly 2 million patients treated for opioid dependence with buprenorphine. That leaves substantial room for conversion to long-acting therapy within a segment where we estimate Brixadi, based on preliminary company data and adjusting for pathology, now holds about 30% of equivalent units. Braeburn has made significant investment in its US organization this quarter to expand both the commercial field force and medical affairs to support that growth. Taken together, with an expanding market, growing share and increased investment behind the brand, we see substantial further growth potential for Brixadi in the US, now moving across to Oczyesa in Germany. The launch continued according to plan, with 4 million SEK sales in the quarter and very positive patient and physician feedback. Our focus for the second half is broadening adoption and moving towards a double-digit share of acromegaly patients on somatostatin receptor agonists. The commercial capabilities we're building here are also helping prepare the ground for CAM2029 in GEP-NET, and the rollout is also extending beyond Germany. Oczyesa is now available in Sweden, with the first patient treated and a formal launch meeting scheduled for September. Processes are progressing in the UK with the national reimbursement process. The first outcomes are expected later in the year. So on this note, I'll hand back to Fredrik.
Thank you, Richard. And let me first turn to the pipeline, where CAM2029 remains the central near-term value driver for us. So CAM2029 is a broad opportunity built around a long-acting octreotide with potential across acromegaly, gastroenteropancreatic neuroendocrine tumours, and polycystic liver disease. The key point is that this is not a single indication asset. It is a drug compound and delivery platform with multiple clinically validated opportunities beyond acromegaly. The ACROINNOVA 1 programme is completed and it is being communicated at various medical conferences and elsewhere. Oczyesa is approved in the UK and EU, and the European launch is underway. The FDA issued a complete response letter for Oczyesa in June. Importantly, this relates to observations during a previous GMP manufacturing inspection at the third-party site and not to the efficacy or safety profile of CAM2029. Those observations have now been addressed, and a new PDUFA target action date is the next important regulatory milestone for the programme. Our view of the clinical profile and commercial opportunity for CAM2029 remains unchanged. Our largest near-term opportunity, though, is gastroenteropancreatic neuroendocrine tumours, a substantial and growing market with considerable unmet medical needs. SORENTO is the largest randomized study of a somatostatin receptor ligand in GEP-NET to date and is our most important pipeline catalyst this year. The study has been fully enrolled since the end of 2023, and based on current event accrual, we expect to reach the target of 194 progression-free survival events in the fourth quarter, followed by the readout of primary results. A positive outcome for CAM2029 in NET would support the compound as a new first-line treatment option, opening a very meaningful new growth avenue for Camurus. Finally, in polycystic liver disease, the positive POSITANO phase two results were presented and recognized at this year. EASL conference in Barcelona, a leading hepatology event. We hold orphan drug designations in the US and EU for PLD and ADPKD, and have completed the FDA end-of-Phase 2 meeting this year; the extension study is currently ongoing, which, together with the feedback, will form the basis for the decision around the continued Phase 3 programme. Beyond CAM2029. Our earlier-stage pipeline gives us additional exposure to large therapeutic areas, while allowing us to leverage the same long-acting delivery experience that underpins our commercial portfolio. CAM2056 is our once-monthly semaglutide depot based on the FluidCrystal technology. During the quarter, we completed a Type B meeting with the FDA, and the regulatory submission package for the Phase 2b clinical trial has been prepared. The study remains on track to start in the second half of the year. Building on the positive phase 1b data reported in November, product design work is also ongoing in parallel, including validation of an autoinjector pen to support simple, once-monthly dosing. We see a meaningful opportunity for once-monthly incretin therapies overall, particularly given the adherence challenges seen for current weekly and daily treatments. Our collaboration with Eli Lilly is progressing to plan. During the quarter, Lilly exercised its option to include amylin agonists, expanding the scope of the partnership beyond the dual and triple incretin agonists that we had already started. We. We view this as a further external validation of the FluidCrystal technology and its potential in the long-acting metabolic medicine space. With Gubra, we have selected the lead compound for our long-acting parathyroid hormone analogue program and are advancing into further development. Taken together, these programs provide several independent opportunities to create value across large and underserved therapeutic areas, supported by our own development capabilities and two well-resourced partners. Let me close with a brief quarterly summary and the priorities ahead. Our strategy rests on four clear priorities: first, commercial execution, extending our leadership in the opioid dependence area with Buvidal and Brixadi and advancing the Oczyesa launch in Europe, strengthening the readiness and broadening the CAM2029 commercial efforts. Second, advancing our pipeline with multiple near-term catalysts. The SORENTO readout in GEP-NET, the start of the CAM2056 phase 2b trial, and the US resubmission pathway for Oczyesa, alongside progress in the broader portfolio. Third, partnerships and business development. We are progressing our collaborations with Eli Lilly and Gubra, and we remain active in evaluating opportunities that can broaden our pipeline and add long-term value for the company; and fourth, financial strength. We have been sustainably profitable since 2022 and ended the quarter with 4.1 billion Swedish kronor in net cash, giving us the means to invest behind our launches, pipeline, and business development opportunities, while maintaining strategic flexibility. The second quarter showed our model is working with record product sales, strong profitability, disciplined investment, and a robust balance sheet. We now enter a catalyst-rich second half with clear priorities: commercial execution, pipeline advancement, and selective capital deployment with strong momentum across the business. We are well-positioned to continue creating value for patients and, of course, also for shareholders. And with that said, we are ready for the first question.
Thanks, operator. The first question is from Gonzalo Artiach Castañon from Danske Bank. Please go ahead. Gonzalo, your line is open.
Hi. Thank you very much for taking my questions and congrats on the good quarter. My first question is on Buvidal, and you mentioned in the report a strong performance in the Nordics, Germany, Spain, and France. Just to get some clarity, is the growth this quarter in any part driven by stocking in any of these regions that we should account for in future estimates. And how should we look at these regions moving forward? I will continue with another question after.
Okay. I will leave it to Richard to respond.
No, it was underlying demand. The growth was broad, as we said, across the countries. As you mentioned, Nordics, Germany, Spain, and France are all considered, alongside the UK growing as well. And there were no one-off effects in the quarter.
Great. Thank you very much. One question on Q3. Q3 tends to not be the best quarter for Buvidal in Europe due to the holiday season. How much are you expecting this to affect Q3? Is the second half of this year especially back-end loaded in your estimates, or how should we see this?
I think it's difficult to give any predictions about Q3. We do not expect to see any significant impact. Generally speaking, we have seen in the past years relatively okay Q3 developments, and I think it is too early for us to give any other indications.
Okay. Perfect. One last question. It is on the CRL in the US. Could you clarify what is the status of the contract manufacturer you are setting up in the US right now? And I know you cannot give many details right now, but what would be the reasons to remain with the contract manufacturer you have in Europe on the back of the CRL you have received and not move straight to the US line with your other partners there. Thank you so much.
Well, I think that, to be frank, our current manufacturer has been capable and able to deliver. Unfortunately, we have received this CRL. So that is something we are accounting for. But strategically, we have decided to build out and make sure that we are not relying on a single manufacturing unit. We need to have broader capabilities and that is the reason, but I do not think we can say anything further on that. If you're looking at the commercial supply performance and also the regulatory discussions with other authorities, we have not seen any issues with current supply.
Great. Thank you very much.
The next question is from Romy O’Connor from Van Lanschot Kempen. Please go ahead.
Yes. Hi, this is Zoe on for Romy. Thank you so much for taking our questions. I have two questions. You noted that the outstanding FDA comments have been addressed and that a further regulatory update is expected soon for the Oczyesa US approval. Can you help us understand what still needs to happen before this resubmission? And do you still think this is going to be a 2026 resubmission, or is it more likely for 2027?
From our standpoint, the remediations have been completed. And that means remediations in relation to the CRL we received on the 10th of June this year. As you know, these were, as we said, third-party related. On the other hand, there was a small point also regarding the oxygen scavenger, and that has also been addressed. So we are hopeful that we will have a resubmission confirmation as soon as possible, but we are not giving any further details at this moment. But I think 2026 is clearly an opportunity.
Okay. Thank you so much. And my second question is, are you able to outline the differences between the two CRLs that you received?
Not really, because, essentially, they were very similar in the sense that there had not been an inspection. And therefore, you can say that the earlier issues remained. So that is the situation. We believe the manufacturer has been in contact with the agency and we believe that this communication has also provided an inspection readiness declaration. So we are expecting. The agency most likely will do an inspection at some point. But that is obviously up to the FDA. It is up to the FDA and not us.
Yes, I understand. Okay. Thank you so much.
Next question is from Shan Hama from Jefferies. Please go ahead.
Hi there. Thanks so much for taking my questions. I have three, if I may. Just to continue on the Oczyesa CRL, has the manufacturer communicated that they expect an inspection to definitely happen this time around? Or is that still uncertain?
I would say that, considering the circumstances, it is highly likely that there will be an inspection of the manufacturer.
Understood. And then my second question, please. Is there a ballpark figure you could provide us with on the size of the Braeburn sales force in the US, and what kind of commercial investments are being made there?
Well, I think not. Aside from what we have said earlier, I cannot say that they have made a significant addition to both their commercial customer-facing sales force and medical team in the last quarter. They are currently on par with other companies in the space.
Understood. And my final question, if I may. At what point during the year will you get further visibility into supply for Buvidal? To the UK. As in, should we be expecting an acceleration in the second half of this year based on your current visibility?
I think as Richard said, we have a process where we have a lot of contributors behind our growth. We are expecting the UK to develop in a positive direction. It is difficult to give you any direct indications of when this will happen, but we are already seeing some positive trends. So overall, we think that will be helpful. And obviously, there are also other discussions and processes ongoing. So we will see how it evolves. But so far, it is looking positive. And I think the most important thing is that we see stable growth across European markets at this point, as Richard already alluded to.
Thanks so much.
Next question from Filip Wiberg from Pareto Securities. Please go ahead.
Hi. Good afternoon. I have a couple of questions on Australia, where you seem to have had a bit of a cautious tone in the report. So firstly, just on the competitor here that we are moving towards at the end of this year. So you now have approximately 80% market share. Do you anticipate capturing that last 20% fairly quickly during 2027? Or how should we think about the dynamics there? Or do you think some patients will switch back to orals, for instance?
I believe it is important to maintain continuity of care. We are doing what we can on the medical side to make sure that we assist in any necessary transfers. And what we have seen in previous transfers. In the Nordics, for instance, it has been largely the case that most patients have been transferring over to Buvidal. According to our reports, it has gone very swiftly. So if we see the same trend as we have seen in the European countries, it should be a vast majority and it has happened on reasonably short notice. So I would say that, yes, shortly after the supply runs out at the end of '26, there should be a transition secured.
Okay. Okay. Very good. And then just on the overall long-acting market in Australia as well. I believe you stated you have a 31% share of all patients now on buprenorphine in Australia. And you previously talked about the possibility of reaching about 50%. So. So, are you still feeling confident about that? And can you talk a little bit about what specifically needs to change for the market to expand to that level?
I can start and leave it over to Richard. I think that the 50% target is a scenario in the future, so to speak. But we definitely see that we already have over 30%, and adding the patients brings us to about 36% of patients now currently standing on long-acting injectables. So it's been a very successful entry into the market. Richard, do you want to comment?
Australia is still growing. I mean, even without the opportunity with the other long-acting product being withdrawn. So it's still growing. There are some capacity issues in the market. It is about patients accessing treatment per se. It is not there, but we are working very closely with the clinics. We're doing a lot of programs, for example, pharmacy injection, which relieves capacity in the clinics because patients then can go to the pharmacy and have their injection and move on. And that's been a successful program in a number of states. And we are rolling that out further as well now.
And maybe I should add to that also, that in Australia, there is still about 40% of patients who are being treated with methadone, and we are seeing an increasing flux of patients from methadone to buprenorphine. So that is another positive source of potential growth and patients in the future.
Okay. Thanks. And perhaps lastly, just related to that, you stated the year-to-date growth in Australia was 6%. So, is it reasonable to expect that growth will stay in the single digits due to these capacity constraints in the near term? Or do you see that you could penetrate the market and accelerate the growth back to double digits, for instance.
I think we will update on that in Q3.
Okay. Thanks. That is all for me.
Next question from Christopher Uhde from SEB. Please go ahead. Christopher.
Christopher Uhde, thank you very much for taking my questions. My first one is on your SG&A, it was up sharply, as was expected, I guess, ahead of the presumptive U.S. launch of Oczyesa. But that is of course now been delayed. And at the same time, you note you've beefed up your Australian sales force and obviously you're busy rolling out Oczyesa in the EU. So how should we model the cadence of SG&A over the remainder of '26 and into '27? Consensus is modeling a 30% year-on-year increase in 2027 to 30% of sales. Are you comfortable with consensus SG&A expectations? That is my first question.
Yes. So, from our side, what we saw in the first half is that we prepared for the launch, of course. And then we had an increase also across the globe. So half of the increase in SG&A came from the US and half from the rest of the world. So it is a balance. Of course, there were some upfront investments in the US, and that of course depends on when we will have potential approval and when we will hire the sales force. But I think it's fine. The assumptions you have are fine; one comment I could make, especially on the R&D, is on the R&D costs for Q2. There was some capitalization of some products because now we have launched in acromegaly. That has offset some of the costs we would normally take and capitalize, which is around 20 million. We have accounted for this in the Q2 numbers for R&D.
Okay. Thank you very much. And then, you've said that your competitor has about a 20% share and obviously plans to exit Australia. So should we just assume a 25% ramp for you between now and year-end, or should it be from year-end? Just a clarification there. And then. How much of your ex-Europe sales of Buvidal are actually from Australia, if you would not mind sharing that?
On the first note, I think it's difficult to make any assumptions at this point because this is recent news and we have not. We have not. But obviously, there are somewhere around 4,000 to 5,000 patients that are currently standing on the other long-acting injectable product. And they will reasonably be transferred over time until the product is fully withdrawn from the market. So I think based on that, I think it's anybody's guess, but I think those are the fundamentals here. Unless something surprising happens, I have difficulty being more precise than that. And Richard, regarding the follow-up question there.
Could you remind me what the question was?
Ex-Europe sales, what proportion is Australia?
I think maybe I can say we are not really comfortable giving that breakdown right now because it varies very much from quarter to quarter.
Okay, thanks.
Australia is a very important market for us, as you can see.
If I could just ask one more question, it would be on the Phase 2b SORENTO trial. Can you tell us now about the design, and particularly the size, duration, and dose levels, please?
We will provide an update as soon as we have that approved and on track. So, that should probably come relatively shortly. So we will update.
Thank you.
Very much. Thank you. It will be a placebo-controlled trial this time.
Thanks very much.
Next question is from Georg Tigalonov-Bjerke from AB. Please go ahead. Georg.
Hello, this is Georg from ABG. Thank you for taking my questions. I have two questions, please. So first, regarding SORENTO, can you clarify if. Also, the announcement of the initial data can be expected in Q4 of this year. And then secondly, have you seen any recent net price changes for Buvidal or Brixadi?
So when it comes to the first question on SORENTO. I think. Regarding the timing. Yeah, yeah. No, the timing of results depends on the timing of reaching the events. So obviously, it will depend on when we reach the target number of events. So if that comes earlier in the quarter, we might have delivery of results in the quarter. If it comes later, there may be a gap, of course, between reaching the number of events and reading out full data.
On the pricing, both Buvidal and Brixadi are pretty stable. There is, of course, a country mix that comes into play depending on the volumes in each country, but generally in the market, the prices are very stable.
Okay, great. Thank you.
There are no more questions at this time. So I hand it back to you for closing comments.
Okay. Thank you, everyone, for attending the call. It was a pleasure as always, and I wish you all a continued nice summer. We look forward to speaking with you again at the Q3 report or earlier.



















